Interim results from a retrospective multicenter European study presented PET-based response criteria as an earlier marker of treatment activity in IDH-mutant glioma treated with vorasidenib. Using PET RANO 1.0 on amino-acid PET, investigators reported partial responses in 29% of evaluable patients versus 6% when assessed with RANO 2.0 MRI criteria. The reported median time-to-response was shorter with PET RANO 1.0 at four months versus eight months by MRI, and metabolic tumor volume change drove the early discriminator. The work adds evidence that serial metabolic imaging may better capture early activity than structural MRI in IDH-mutant disease under therapy.